Features Partner Sites Information LinkXpress
Sign In
Demo Company

European Bioinformatics Sector Expected to Surge

By BiotechDaily International staff writers
Posted on 01 Jun 2014
Print article
An intra-European purchase agreement will boost the bioinformatics field by combining an exhaustive genomics data base with a highly intuitive software suite.

Qiagen N.V. (Venlo, The Netherlands) will be expanding its industry-leading portfolio of bioinformatics solutions called "Ingenuity Knowledge Base" by incorporating the genomics analysis and sequencing data that comprises the Biobase (Wolfenbüttel, Germany) HGMD (Human Gene Mutation Database) and PGMD (PharmacoGenomic Mutation Database) databases.

HGMD provides comprehensive data on human inherited disease mutations. Widely used in human genetics research, diagnostics, and personal genomics, HGMD enables quick access to single mutation queries and advanced search applications. PGMD identifies all published gene variants that have been shown to affect drug response in patients, with multiple delivery models for accessing this data, including an intuitive exploratory interface and a data download for in-house analysis systems.

“The ability of next-generation sequencing (NGS) to rapidly deliver genomic insights is opening up new frontiers for clinical research and medicine, and Qiagen is strategically addressing customers’ needs to interpret the massive amounts of data generated by NGS. With HGMD and other content from Biobase, a respected organization with a dedicated team and robust line of unique databases and software, Qiagen is further extending its competitive advantage as the overall market leader for clinical interpretation of human sequencing data,” said Peer M. Schatz, CEO of Qiagen. “Already today, more than 15,000 users worldwide rely on Qiagen’s bioinformatics products for interpretation and have processed over a quarter of a million genome sequences. HGMD is a unique fit with our offering and will integrate well. We expect to drive additional adoption of this leading literature-based knowledge base used by clinical reference labs for annotating hereditary variants, as well as Biobase’ other solutions by having integrated them into interpretation solutions shared with our Ingenuity Knowledge Base, adding value for Qiagen and Biobase customers and accelerating our growth drivers in NGS and bioinformatics.”

When the acquisition has been completed, Biobase will be renamed Qiagen Wolfenbüttel.

Related Links:
Qiagen N.V.

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.